Clinical Trials Logo
  1. Home
  2. Ebola Virus Disease
  3. NCT04815174
  4. Details
NCT04815174 Clinical Trial

Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease

Ebola Virus Disease Clinical Trial

— EVISTA  

Official title:
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04815174
Other study ID # ALIMA01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2018
Est. completion date December 31, 2019

Study information
Verified date March 2021
Source Alliance for International Medical Action
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study highlighted the possibility, even in epidemic settings, of providing advanced supportive care for patients with VMEs. Indeed, while the prospect of offering any invasive medical care was widely discussed in 2014 in West Africa with the aim of limiting the exposure of caregivers, the epidemic of 2018-2019 has on the contrary seen the development of a number of medical care strategies, in parallel with the deployment of specific treatments. This study aims to describe a cohort of patients receiving this upgraded supportive care during the tenth epidemic in the DRC.

Recruitment information / eligibility
Status Completed
Enrollment 711
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Laboratory confirmed Ebola Virus Disease Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Standard of Care
(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.

Locations
Country Name City State
Congo, The Democratic Republic of the BENI ETC Beni Nord Kivu

Sponsors (1)
Lead Sponsor Collaborator
Alliance for International Medical Action

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome
Type Measure Description Time frame Safety issue
Primary Mortality Any type mortality during hospitalization Through the end of the hospitalization, with an average of 11 days
See also
  Status Clinical Trial Phase
Completed NCT00374309 - Experimental Vaccine for Prevention of Ebola Virus Infection Phase 1
Completed NCT03098862 - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed NCT02509494 - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Phase 3
Recruiting NCT06093646 - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda N/A
Completed NCT02495246 - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Phase 1
Completed NCT04906629 - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees Phase 1
Completed NCT05064956 - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Phase 2
Not yet recruiting NCT06126822 - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Phase 3
Withdrawn NCT04268966 - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola Phase 2
Completed NCT02267109 - Phase 1 Trial of Ebola Vaccine in Mali Phase 1
Not yet recruiting NCT04822376 - Prophylaxis Vaccine Antibodies Ebola Phase 2
Recruiting NCT02333578 - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment N/A
Completed NCT02662855 - Efficacy of Favipiravir Against Severe Ebola Virus Disease Phase 2
Active, not recruiting NCT04152486 - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC Phase 3
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed NCT03161366 - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Phase 3
Completed NCT03140774 - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended NCT03462004 - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Phase 1
Active, not recruiting NCT02876328 - Partnership for Research on Ebola VACcinations Phase 2
Not yet recruiting NCT05202288 - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Phase 2